Clinical Trial Update: A Study of Neoadjuvant QL1706 in Participants With Untreated dMMR/MSI-H Resectable Colon Cancer [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating neoadjuvant QL1706 in untreated dMMR/MSI-H resectable colon cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colon Cancer

Drugs mentioned

• QL1706

Snippet

Sponsor: Qilu Pharmaceutical Co., Ltd. | Conditions: Colon Cancer | Phase 3 | Status: RECRUITING